Home/Filings/4/0001104659-22-119974
4//SEC Filing

Liu David Y 4

Accession 0001104659-22-119974

CIK 0001377121other

Filed

Nov 16, 7:00 PM ET

Accepted

Nov 17, 6:24 PM ET

Size

27.5 KB

Accession

0001104659-22-119974

Insider Transaction Report

Form 4
Period: 2022-11-16
Liu David Y
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2022-11-16$0.87/sh+13,767$11,97780,878 total
  • Exercise/Conversion

    Common Stock

    2022-11-16$1.89/sh+5,999$11,33896,603 total
  • Exercise/Conversion

    Common Stock

    2022-11-16$1.16/sh+35,656$41,361132,259 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2022-11-1613,7670 total
    Exercise: $0.87Exp: 2023-09-26Common Stock (13,767 underlying)
  • Exercise/Conversion

    Common Stock

    2022-11-16$1.89/sh+9,726$18,38290,604 total
  • Exercise/Conversion

    Common Stock

    2022-11-16$4.21/sh+35,331$148,744167,590 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2022-11-169,7260 total
    Exercise: $1.89Exp: 2024-10-22Common Stock (9,726 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2022-11-165,9990 total
    Exercise: $1.89Exp: 2025-03-26Common Stock (5,999 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2022-11-1635,6560 total
    Exercise: $1.16Exp: 2025-10-28Common Stock (35,656 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2022-11-1635,3310 total
    Exercise: $4.21Exp: 2026-04-29Common Stock (35,331 underlying)
Footnotes (2)
  • [F1]Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022.
  • [F2]The stock option is vested in full.

Issuer

Protagonist Therapeutics, Inc

CIK 0001377121

Entity typeother

Related Parties

1
  • filerCIK 0001675881

Filing Metadata

Form type
4
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 6:24 PM ET
Size
27.5 KB